Cytokinetics, Inc.
http://www.cytokinetics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cytokinetics, Inc.
Edgewise’s Early Cardiomyopathy Data Builds Case For A Blockbuster
The EDG-7500 results have seen the company’s share price rocket, thanks to a potential advantage over existing treatments for the rare heart condition hypertrophic cardiomyopathy.
US Approvals Of Novel Drugs Set To Hit 10-Year High In 2025
But 2024 will see a lull between two strong years.
2025’s Therapy Area Growth Drivers And Brakes: Part Two
The second instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on blood malignancies, skin conditions and generalized cardiovascular disease.
US Approvals Of Novel Drugs Set To Hit 10-Year High In 2025
But 2024 will see a lull between two strong years.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice